Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxyzine is a first-generation antihistamine in the piperazine class. It is used to treat itching caused by allergic skin reactions and as an anxiolytic for anxiety and tension in adults and children. Hydroxyzine also serves as a sedative before and after general anesthesia and can be used to manage nausea or vomiting. Its mechanism of action involves blocking histamine H1 receptor (antagonism), thereby reducing allergic symptoms such as itching; it also decreases activity in the central nervous system leading to its sedative and anxiolytic effects. Hydroxyzine was first developed by Union Chimique Belge in 1956 and later approved for sale by Pfizer[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxyzine.